Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11940791 | 0.89 | HTR2C (0.40) | TRPV3IDO1PDE10AOPRL1 | |
| SCHEMBL29487568 | 0.89 | HTR2C (0.40) | TRPV3IDO1PDE10AOPRL1 | |
| SCHEMBL12906947 | 0.84 | PDE10A (0.33) | TRPV3IDO1PDE10A | |
| SCHEMBL10091334 | 0.84 | PDE10A (0.36) | TRPV3IDO1PDE10AOPRL1ALDH1A1 | |
| SCHEMBL24497738 | 0.81 | TRPV3 (0.42) | TRPV3NPC1RAB9AIDO1ALDH1A1 | |
| SCHEMBL22857372 | 0.81 | TRPV3 (0.37) | TRPV3NPC1RAB9AIDO1PDE10A | |
| SCHEMBL12716556 | 0.80 | TRPV3 (0.31) | TRPV3PDE10A | |
| SCHEMBL15722917 | 0.80 | HTR2C (0.36) | TRPV3NPC1RAB9AIDO1PDE10A | |
| SCHEMBL17542866 | 0.80 | OPRL1 (0.47) | TRPV3NPC1RAB9AOPRL1ALDH1A1 | |
| SCHEMBL29932014 | 0.80 | OPRL1 (0.47) | TRPV3NPC1RAB9AOPRL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882856-B2 | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases | BEIGENE, LTD. (KY) | 2021-01-05 | — | — | US | disclosed |
| US-10882856-B2 | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases | BEIGENE, LTD. (KY) | 2021-01-05 | — | — | US | disclosed |
| WO-2018054365-A1 | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES | BEIGENE, LTD. (KY) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882856-B2 | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases | IDO1, TPH1, IDO2 | TRPV3 1958/4885NPC1 3887/4885RAB9A 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.